- Global Pharma News & Resources

CellGenix Appoints Daniel Spatz as Vice President Sales, Marketing & Logistics and Member of the Management Team

FREIBURG, Germany, April 12, 2021 / B3C newswire / -- CellGenix, a global manufacturing leader of GMP-grade raw materials for cell therapy, gene therapy and tissue-engineered products, is pleased to announce the appointment of Daniel Spatz as Vice President Sales, Marketing & Logistics and member of the management team.

Daniel joined CellGenix in 2021 as Head of Marketing & Sales and Logistics. He is responsible for the entire global sales and marketing organization as well as the logistics and customer service organization for our headquarters in Germany. He will now represent these important areas in the management team and will contribute to further strengthening our global presence as premium raw material supplier. The management team is completed by Prof. Dr. Felicia M. Rosenthal (Chief Executive Officer), Dr. Bernd Leistler (Vice President Production), Dr. Udo Nirenberg (Vice President Quality Management), Dr. Till Puschmann (Vice President R&D and Business Development).

“We are delighted to welcome Daniel Spatz in our management team,” said Prof. Felicia Rosenthal, CEO of CellGenix. “Daniel has extensive global marketing and sales experience in the life science field and a proven track record. I am confident that he will prove to be an important addition to our management team as CellGenix continues to expand and build on its leading position as premium supplier of high-quality raw materials for cell and gene therapy manufacturing. We welcome him in our management team and look forward to continue working with him.”

“I am very excited to join the management team of CellGenix and help build on the solid foundation developed over the last 25+ years”, said Daniel Spatz. “With comprehensive knowledge and hands-on experience of developing a cell therapy ourselves, CellGenix is an expert in GMP manufacturing of raw materials for cell and gene therapies. I am looking forward to sharing my vast experience and know-how to continue to drive CellGenix’ growth in the cell and gene therapy market and ensure continuous and optimal customer support.”

Daniel started his professional career in 1996 as Account Manager tissue culture products at Becton Dickinson GmbH in Germany, a leading multinational medical and life science manufacturer. In the following years he took over several leading positions in sales and marketing for the BD Biosciences business unit Central Europe and was part of the leadership team. Before joining CellGenix Daniel was responsible as CBO for the global sales and marketing organization at PromoCell GmbH, a premier manufacturer for primary cells and media. He holds a degree in business administration as Bachelor of Arts from DHBW Mannheim, Germany.

Caption: Daniel Spatz


About CellGenix
CellGenix is a leading global supplier of high quality raw and ancillary materials for the expanding market of cell and gene therapy and regenerative medicine. CellGenix develops, manufactures and markets human cytokines, growth factors, and other recombinant cell culture components in preclinical and GMP quality as well as proprietary serum-free media for further manufacturing of ATMPs. As a former ATMP developer and manufacturer, in more than two decades CellGenix gained in-depth cell processing knowledge and superior regulatory expertise. With this unique background, CellGenix understands the high requirements their customers are facing during product development and the regulatory approval process. To meet the increasing demand of GMP quality raw materials for ATMP manufacturing CellGenix has recently expanded manufacturing capacity, built additional R&D and QC laboratories, and warehouse space. The upgrade also introduced state-of-the-art, automated, large-scale capacities for recombinant protein products in the existing GMP facilities. CellGenix is headquartered in Freiburg, Germany and operates a subsidiary near Boston in Portsmouth, USA.



CellGenix GmbH
Prof. Dr. med. Felicia M. Rosenthal
Chief Executive Officer
+49 761 88889100


Keywords: Cytokines; Genetic Therapy; Cell- and Tissue-Based Therapy; Regenerative Medicine; Culture Media, Serum-Free; Indicators and Reagents; Manufactured Materials; Cell Culture Techniques; Freeze Drying: Marketing; Commerce; Germany


Published by B3C newswire

Editor Details

Last Updated: 12-Apr-2021